|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.93 USD | -2.14% |
|
+2.30% | -2.14% |
| 04:34am | Ionis, AstraZeneca Report Amyloid Cardiomyopathy Treatment Failed to Meet Primary Endpoint in Phase 3 | MT |
| 04:30am | AstraZeneca shares slump after clinical trial fails |  |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AZN Stock
- AZND Stock
- Consensus AstraZeneca PLC
- Estimates Revisions
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
